Targeted agents in acute myeloid leukemia in elderly patients
Antifungal prophylaxis in leukemia patients
Is gilteritinib the new breakthrough in the treatment of FLT3-mutated AML?
The success story of indolent disease treatment expanded to difficult-to-treat patient groups
Results of the Phase III DASISION trial and the future of CML treatment